Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
FOXO4-D-Retro-Inverso
FOXO4-DRI is a D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells. It is studied as a senolytic agent that selectively induces apoptosis in senescent cells while sparing normal cells.
In senescent cells, FOXO4 sequesters p53 in PML nuclear bodies, preventing apoptosis. FOXO4-DRI competitively disrupts this interaction, releasing p53 to trigger the intrinsic apoptosis cascade. The D-retro-inverso modification (D-amino acids in reverse sequence) resists protease degradation while maintaining binding affinity. Selectivity arises because the FOXO4-p53 interaction is specifically upregulated in senescent cells.
Baar et al. (Cell, 2017) demonstrated that FOXO4-DRI selectively induced apoptosis in senescent fibroblasts in vitro and, when administered to fast-aging and naturally aged mice, restored fitness, fur density, and renal function with reduced senescent cell burden. No human clinical trials have been initiated.
Typical Dose
5-10mg/kg
Frequency
Every 3 days for 3 doses (murine protocol)
Route
SubQ, IV
Notes
Dosing from Baar et al. (2017) murine study: 5mg/kg IP every 3 days x3. Lyophilized powder, reconstitute with bacteriostatic water. Store at -20°C; reconstituted use within 7 days. Large peptide (~3.5 kDa) with limited scaling data.
Build a protocol with FOXO4-DRI, schedule blood work for key biomarkers, and track your results.
Build Protocol with FOXO4-DRIThis platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.
Disclosed Labs